Prelude Therapeutics Incorporated (PRLD) – What Are Brokerages Saying About This Stock?

Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD – Get Free Report) have received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $8.75.

A number of research firms recently commented on PRLD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Tuesday, October 27th. Wall Street Zen downgraded shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. Citigroup reissued a “market outperform” rating on shares of Prelude Therapeutics in a report on Wednesday, October 14th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Prelude Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. initiated coverage on shares of Prelude Therapeutics in a report on Thursday, September 17th. They set an “overweight” rating and a $12.00 target price on the stock.

Check Out Our Latest Stock Analysis on Prelude Therapeutics

Hedge Funds Weigh In On Prelude Therapeutics

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Prelude Therapeutics in the 2nd quarter valued at approximately $9,581,000. ADAR1 Capital Management LLC acquired a new stake in shares of Prelude Therapeutics during the 2nd quarter worth approximately $4,802,000. EcoR1 Capital LLC bought a new position in Prelude Therapeutics in the first quarter valued at approximately $3,239,000. Goldman Sachs Group Inc. increased its stake in Prelude Therapeutics by 451.8% in the third quarter. Goldman Sachs Group Inc. now owns 666,778 shares of the company’s stock valued at $2,607,000 after acquiring an additional 545,944 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Prelude Therapeutics by 1.4% in the first quarter. Renaissance Technologies LLC now owns 275,200 shares of the company’s stock valued at $941,000 after acquiring an additional 3,900 shares during the last quarter. 79.72% of the stock is owned by institutional investors.

Prelude Therapeutics Stock Down 1.2%

NASDAQ:PRLD opened at $3.26 on Friday. Prelude Therapeutics has a twelve month low of $1.29 and a twelve month high of $6.83. The firm has a market capitalization of $260.15 million, a price-to-earnings ratio of -5.53 and a beta of 1.22. The stock’s 50 day moving average price is $3.86 and its two-hundred day moving average price is $4.10.

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.13). The business had revenue of $5.65 million during the quarter, compared to analysts’ expectations of $29.00 million. As a group, analysts anticipate that Prelude Therapeutics will post -0.57 earnings per share for the current year.

Prelude Therapeutics Company Profile

(Get Free Report)

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

See Also

Analyst Recommendations for Prelude Therapeutics (NASDAQ:PRLD)

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.